5/11/2011 10:23:54 AM
InNexus Biotechnology Inc. (TSX:IXS.V), a leading drug development company commercializing the next generation of antibodies based on its proprietary DXL™ and Transmab™ technologies, today announced that it has appointed Christie Amato as its Chief Financial Officer. Mrs. Amato replaces David Petulla and assumed her new position on May 9th 2011. She will oversee InNexus non-research and development administrative functions in addition to her financial management responsibilities.
comments powered by